UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Directly observed therapy of chronic hepatitis C with ledipasvir/sofosbuvir in people who inject drugs at risk of nonadherence to direct‐acting antivirals

Journal of viral hepatitis, 2018-07, Vol.25 (7), p.870-873

2018

Volltextzugriff (PDF)

Polymorphisms of interferon- lambda 4 and IL28B - effects on treatment response to interferon/ribavirin in patients with chronic hepatitis C

Alimentary pharmacology & therapeutics, 2014-01, Vol.39 (1), p.104-111

2014

Volltextzugriff (PDF)

Polymorphisms of interferon‐λ4 and IL28B – effects on treatment response to interferon/ribavirin in patients with chronic hepatitis C

Alimentary pharmacology & therapeutics, 2014-01, Vol.39 (1), p.104-111

2014

Volltextzugriff (PDF)

Combining treatment for chronic hepatitis C with opioid agonist therapy is an effective microelimination strategy for people who inject drugs with high risk of non-adherence to direct-acting antiviral therapy

Journal of Virus Eradication, 2023-03, Vol.9 (1), p.100319-100319, Article 100319

2023

Volltextzugriff (PDF)

Directly observed therapy with sofosbuvir/ledipasvir for 8 weeks is highly effective in treatment-naïve, precirrhotic genotype 1 patients with borderline compliance receiving opioid agonist therapy

Journal of hepatology, 2017, Vol.66 (1), p.S740-S740

2017

Volltextzugriff (PDF)

Child-Pugh versus MELD score in predicting survival in patients undergoing transjugular intrahepatic portosystemic shunt

Gut, 2003-06, Vol.52 (6), p.879-885

2003

Volltextzugriff (PDF)

1108 SELECTION OF HCV GENOTYPE 1 PATIENTS FOR DUAL THERAPY WITH PEGINTERFERON ALFA-2A/RIBAVIRIN WITH A HIGH PROBABILITY OF SUSTAINED VIROLOGIC RESPONSE ACCORDING TO BASELINE CHARACTERISTICS ALONE

Journal of hepatology, 2012-04, Vol.56, p.S436-S436

2012

Volltextzugriff (PDF)

Time to viral suppression is not related to achievement of SVR12 in HCV GT1‐infected patients treated with ombitasvir/paritaprevir/ritonavir and dasabuvir with or without ribavirin

Journal of viral hepatitis, 2017-04, Vol.24 (4), p.280-286

2017

Volltextzugriff (PDF)

Durability of SVR in chronic hepatitis C patients treated with peginterferon‐α2a/ribavirin in combination with a direct‐acting anti‐viral

Alimentary pharmacology & therapeutics, 2013-07, Vol.38 (2), p.118-123

2013

Volltextzugriff (PDF)

MRI of the knee: how do field strength and radiologist’s experience influence diagnostic accuracy and interobserver correlation in assessing chondral and meniscal lesions and the integrity of the anterior cruciate ligament?

European radiology, 2009-06, Vol.19 (6), p.1519-1528

2009

Volltextzugriff (PDF)

Direct Observed Therapy of Chronic Hepatitis C with Interferon-Free All-Oral Regimens at a Low-Threshold Drug Treatment Facility – a New Concept for Treatment of Patients with Borderline Compliance Receiving Opioid Substitution Therapy

Journal of hepatology, 2016, Vol.64 (2), p.S822-S822

2016

Volltextzugriff (PDF)

P766 THE DISEASE BURDEN OF CHRONIC HEPATITIS C VIRUS (HCV) INFECTION IN AUSTRIA

Journal of hepatology, 2014-04, Vol.60 (1), p.S326-S326

2014

Volltextzugriff (PDF)

Letter: retreatment of patients with chronic hepatitis C who have failed interferon‐free combination therapy with direct acting anti‐virals

Alimentary pharmacology & therapeutics, 2017-01, Vol.45 (2), p.373-375

2017

Volltextzugriff (PDF)

Daclatasvir plus Sofosbuvir with or without Ribavirin for the Treatment of Chronic HCV Infection in Patients with Decompensated Cirrhosis: Results of a European Multicentre Compassionate Use Program

JOURNAL OF HEPATOLOGY, 2016, Vol.64 (2), p.S781-S782

2016

Volltextzugriff (PDF)

Daclatasvir plus Sofosbuvir with or without Ribavirin for Treatment of Chronic HCV Infection in Patients with Advanced Liver Disease: Results of a European Compassionate use Program

JOURNAL OF HEPATOLOGY, 2016, Vol.64 (2), p.S825-S825

2016

Volltextzugriff (PDF)

P0792 : Baseline factors associated with increased SVR rates in 123 treatment-naïve chronic HCV genotype 1 patients treated with a shortened 12-week simeprevir plus pegylated interferon and ribavirin regimen: a multivariate analysis

Journal of hepatology, 2015-04, Vol.62, p.S629-S630

2015

Volltextzugriff (PDF)

P0740 : Usefulness of interferon LAMBDA4-, HLA class II-polymorphism and killer-immunglobulin -like receptor-2DL3:C1/C1 to predict spontaneous clearance of acute hepatitis C virus infection

Journal of hepatology, 2015-04, Vol.62, p.S602-S603

2015

Volltextzugriff (PDF)

P0772 : Daclatasvir plus sofosbuvir with or without ribavirin for the treatment of HCV in patients with severe liver disease: Interim results of a multicenter compassionate use program

Journal of hepatology, 2015-04, Vol.62, p.S619-S620

2015

Volltextzugriff (PDF)

Structured management strategy based on the Gastro-oesophageal Reflux Disease (GERD) Questionnaire (GerdQ) vs. usual primary care for GERD: pooled analysis of five cluster-randomised European studies

International journal of clinical practice (Esher), 2012-09, Vol.66 (9), p.897-905

2012

Volltextzugriff (PDF)

Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort

Gut, 2016-11, Vol.65 (11), p.1861-1870

2016

Volltextzugriff (PDF)

P0783 : Viral kinetics during interferon-free sofosbuvir containing treatment regimens in a real-life cohort of chronic hepatitis C patients with advanced liver disease

Journal of hepatology, 2015-04, Vol.62, p.S625-S625

2015

Volltextzugriff (PDF)

65 SAFETY OF TRIPLE THERAPY WITH TELAPREVIR OR BOCEPREVIR IN HEPATITIS C PATIENTS WITH ADVANCED LIVER DISEASE – PREDICTIVE FACTORS FOR SEPSIS

Journal of hepatology, 2013-04, Vol.58, p.S30-S30

2013

Volltextzugriff (PDF)

Forty years without symptoms after choledochogastrostomy

Endoscopy, 2012, Vol.44 Suppl 2 UCTN (S 02), p.E199-E200

2012

Volltextzugriff (PDF)

1107 PREDICTIVE VALUE OF FIB-4 VS METAVIR ON SUSTAINED VIROLOGICAL RESPONSE IN GENOTYPE 1 CHRONIC HEPATITIS C PATIENTS: FINAL ANALYSIS FROM THE LARGE MULTINATIONAL PROPHESYS TRIAL

Journal of hepatology, 2012-04, Vol.56, p.S435-S436

2012

Volltextzugriff (PDF)

ABT-450/r–Ombitasvir and Dasabuvir with or without Ribavirin for HCV

The New England journal of medicine, 2014-05, Vol.370 (21), p.1983-1992

2014

Volltextzugriff (PDF)

1 – 25 von 225

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(216)
Mit Volltextzugriff
(136)

Publikationsform

Sprache

Englisch
(175)
Deutsch
(79)

Erscheinungsjahr

n.n

Thema

Humans
(77)
Life Sciences & Biomedicine
(74)
Science & Technology
(74)
Female
(53)
Middle Aged
(48)
Gastroenterology & Hepatology
(44)
Adult
(42)
Male
(41)
Aged
(39)
Biological And Medical Sciences
(34)
Medical Sciences
(34)
Hepatitis C, Chronic - Drug Therapy
(21)
Gastroenterology And Hepatology
(17)
Medicin Och Hälsovetenskap
(17)
Pharmacology. Drug Treatments
(17)
Drug Therapy, Combination
(16)
Treatment Outcome
(16)
Genotype
(14)
Hepacivirus - Genetics
(14)
Antiviral Agents - Therapeutic Use
(13)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 7 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Directly observed therapy of chronic hepatitis C with ledipasvir/sofosbuvir in people who inject drugs at risk of nonadherence to direct‐acting antivirals

Polymorphisms of interferon- lambda 4 and IL28B - effects on treatment response to interferon/ribavirin in patients with chronic hepatitis C

Polymorphisms of interferon‐λ4 and IL28B – effects on treatment response to interferon/ribavirin in patients with chronic hepatitis C

Combining treatment for chronic hepatitis C with opioid agonist therapy is an effective microelimination strategy for people who inject drugs with high risk of non-adherence to direct-acting antiviral therapy

Directly observed therapy with sofosbuvir/ledipasvir for 8 weeks is highly effective in treatment-naïve, precirrhotic genotype 1 patients with borderline compliance receiving opioid agonist therapy

Child-Pugh versus MELD score in predicting survival in patients undergoing transjugular intrahepatic portosystemic shunt

1108 SELECTION OF HCV GENOTYPE 1 PATIENTS FOR DUAL THERAPY WITH PEGINTERFERON ALFA-2A/RIBAVIRIN WITH A HIGH PROBABILITY OF SUSTAINED VIROLOGIC RESPONSE ACCORDING TO BASELINE CHARACTERISTICS ALONE

Time to viral suppression is not related to achievement of SVR12 in HCV GT1‐infected patients treated with ombitasvir/paritaprevir/ritonavir and dasabuvir with or without ribavirin

Durability of SVR in chronic hepatitis C patients treated with peginterferon‐α2a/ribavirin in combination with a direct‐acting anti‐viral

MRI of the knee: how do field strength and radiologist’s experience influence diagnostic accuracy and interobserver correlation in assessing chondral and meniscal lesions and the integrity of the anterior cruciate ligament?

Direct Observed Therapy of Chronic Hepatitis C with Interferon-Free All-Oral Regimens at a Low-Threshold Drug Treatment Facility – a New Concept for Treatment of Patients with Borderline Compliance Receiving Opioid Substitution Therapy

P766 THE DISEASE BURDEN OF CHRONIC HEPATITIS C VIRUS (HCV) INFECTION IN AUSTRIA

Letter: retreatment of patients with chronic hepatitis C who have failed interferon‐free combination therapy with direct acting anti‐virals

Daclatasvir plus Sofosbuvir with or without Ribavirin for the Treatment of Chronic HCV Infection in Patients with Decompensated Cirrhosis: Results of a European Multicentre Compassionate Use Program

Daclatasvir plus Sofosbuvir with or without Ribavirin for Treatment of Chronic HCV Infection in Patients with Advanced Liver Disease: Results of a European Compassionate use Program

P0792 : Baseline factors associated with increased SVR rates in 123 treatment-naïve chronic HCV genotype 1 patients treated with a shortened 12-week simeprevir plus pegylated interferon and ribavirin regimen: a multivariate analysis

P0740 : Usefulness of interferon LAMBDA4-, HLA class II-polymorphism and killer-immunglobulin -like receptor-2DL3:C1/C1 to predict spontaneous clearance of acute hepatitis C virus infection

P0772 : Daclatasvir plus sofosbuvir with or without ribavirin for the treatment of HCV in patients with severe liver disease: Interim results of a multicenter compassionate use program

Structured management strategy based on the Gastro-oesophageal Reflux Disease (GERD) Questionnaire (GerdQ) vs. usual primary care for GERD: pooled analysis of five cluster-randomised European studies

Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort

P0783 : Viral kinetics during interferon-free sofosbuvir containing treatment regimens in a real-life cohort of chronic hepatitis C patients with advanced liver disease

65 SAFETY OF TRIPLE THERAPY WITH TELAPREVIR OR BOCEPREVIR IN HEPATITIS C PATIENTS WITH ADVANCED LIVER DISEASE – PREDICTIVE FACTORS FOR SEPSIS

Forty years without symptoms after choledochogastrostomy

1107 PREDICTIVE VALUE OF FIB-4 VS METAVIR ON SUSTAINED VIROLOGICAL RESPONSE IN GENOTYPE 1 CHRONIC HEPATITIS C PATIENTS: FINAL ANALYSIS FROM THE LARGE MULTINATIONAL PROPHESYS TRIAL

ABT-450/r–Ombitasvir and Dasabuvir with or without Ribavirin for HCV

Suchergebnisse filtern